
OABIW — OmniAb Inc.
NASDAQ
$0.30
+$0.07 (+30.43%)
OmniAb Inc. (OABIW) common stock listed on NASDAQ. It is led by Matthew W. Foehr, based in 5980 Horton Street, EmeryVille, CA, United States, 94608, with about 89 employees. OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company offers animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. It has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
Latest reported OABIW revenue for 2025-09-30 was $2.2M. Net income was -$16.5M. Revenue was down 42.5% from 2025-06-30 to 2025-09-30.
Use this OABIW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the OABIW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the OABIW SEC filings page. Lician reads the product cache first so this HTML stays unique to OmniAb Inc. even when a live quote feed is slow.
About OmniAb Inc.
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company offers animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. It has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
OABIW Key Statistics
Market Cap
$0.00M
Volume
14,440
Previous Close
$0.23
Day Range
$0.20 – $0.33
EPS
-$0.61
Revenue
$26.39M
Net Income
-$62.03M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-22.8%
Profit Margin
-235.1%
Employees
89
OABIW Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $26.39M | $34.16M | $59.08M | $34.75M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$62.03M | -$50.62M | -$22.33M | $516.44K |
| EPS (Diluted) | -$0.61 | -$0.51 | -$0.26 | -$0.33 |
Total Assets
$325.56M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$27.60M
Operating Cash Flow
-$39.66M
Free Cash Flow
$0.00
OmniAb Inc. Company Information
- President, CEO & Director
- Matthew W. Foehr
- Headquarters
- 5980 Horton Street, EmeryVille, CA, United States, 94608
- Website
- www.omniab.com
- Phone
- 510 250 7800
- IPO / Founded
- 2021-09-30